Latest Glycogen storage disease type II Stories
CRANBURY, N.J., Jan. 11 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today outlined the Company's three key strategic priorities and presented a corporate outlook for 2010 at the 28th Annual J.P. Morgan Healthcare Conference.
CRANBURY, N.J., Sept. 30 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced it plans to initiate a Phase 1 study of AT2220 (1-deoxynojirimycin HCl), its investigational drug in development for the treatment of Pompe Disease.
Brain may win out over brawn as the primary cause of breathing problems in children with a severe form of muscular dystrophy known as Pompe disease.
CRANBURY, N.J., Feb.
CRANBURY, N.J., Feb. 18 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) announced today that Stephen Bloch, M.D., General Partner with Canaan Equity Partners, has resigned from the Company's Board of Directors effective February 17, 2009. Dr.
CRANBURY, N.J., Jan. 29 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) will announce fourth quarter and full year 2008 financial results after the regular close of markets on Thursday, February 5, 2009.
Company Expects to Deliver Multiple Clinical Milestones throughout the Year; Amigal to Initiate Phase 3 Global Development in Second Quarter; Continued Strong Financial Position CRANBURY, N.J., Jan.
The life of a Minnesota boy suffering with a rare and serious form of the genetic disorder Pompe disease has been extended after treatment with a drug typically used to suppress the immune system of those with cancer and rheumatoid arthritis.
CRANBURY, N.J., Jan. 8 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced the election of Sol J. Barer, Ph.D., to its Board of Directors. Dr. Barer currently serves as Chairman and Chief Executive Officer of Celgene Corporation. As an industry veteran, Dr.
- A transitional zone between two communities containing the characteristic species of each.